MedPath

Study Highlights Efficacy and Safety of SGLT2 Inhibitors in Type 2 Diabetes Management

A recent study evaluates the long-term efficacy and safety of Sodium-glucose co-transporter 2 (SGLT2) inhibitors in managing type 2 diabetes (T2D), revealing significant improvements in glycemic control and body weight reduction. However, it also notes an increased prevalence of adverse events and drug discontinuation, especially among elderly patients.

Introduction

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a pivotal treatment for type 2 diabetes (T2D), offering cardiovascular benefits and improved glycemic control. This study delves into the real-world efficacy and safety of SGLT2 inhibitors, focusing on a diverse patient population.

Study Design and Participants

Conducted at Chungbuk National University Hospital, the study analyzed 715 T2D patients who added SGLT2 inhibitors to their treatment regimen between 2015 and 2019. After exclusions, 596 patients were included, with a focus on elderly (≥75 years) and adult (<75 years) subgroups.

Effectiveness

Significant reductions in HbA1c levels were observed from the initial visit (8.8 ± 1.3%) to the 6-month follow-up (7.5 ± 1.1%), maintaining lower levels throughout the 36-month period. Fasting plasma glucose (FPG) levels and body weight also showed consistent decreases, highlighting the therapeutic benefits of SGLT2 inhibitors.

Safety and Tolerability

The study reported hypoglycemia as the most common adverse event (AE), followed by genitourinary infections (GUI), polyuria, and gastrointestinal issues. Notably, elderly patients experienced a higher incidence of AEs and discontinuation rates compared to their younger counterparts.

Conclusion

While SGLT2 inhibitors demonstrate significant benefits in T2D management, the study underscores the need for cautious use, especially in elderly patients, due to the increased risk of AEs and discontinuation. Further research is essential to optimize treatment strategies and minimize risks associated with SGLT2 inhibitors.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

SGLT2 Inhibitors Show Promise in Managing Chronic Kidney Disease in Real-World Settings

A recent study highlights the effectiveness and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in managing chronic kidney disease (CKD), showing a significant reduction in the risk of major adverse kidney events (MAKEs) compared to traditional RAAS blockade therapy. The study, conducted in a real-world setting, supports the broader application of SGLT2i in CKD management, regardless of diabetic status, aligning with the 2024 KDIGO guidelines.

Sotagliflozin may lower HbA1c without raising risks for adults with type 1 diabetes, CKD

Sotagliflozin, a dual SGLT1/SGLT2 inhibitor, has been associated with lower HbA1c levels in adults with type 1 diabetes and chronic kidney disease (CKD) without increasing the risks of severe hypoglycemia or diabetic ketoacidosis (DKA). This finding comes from post-hoc analyses of data from the inTandem 1, 2, and 3 trials, highlighting the potential benefits of sotagliflozin for this patient population when appropriate steps are taken to mitigate DKA risk.

SGLT2 Inhibitors Show Promise in Cirrhosis Patients, Reducing Complications and Mortality

A recent study indicates that SGLT2 inhibitors are safe for cirrhosis patients, addressing a critical gap in treatment options for this population.
The research found that SGLT2i use is associated with a reduced risk of all-cause mortality and hospitalization in cirrhosis patients.

Semaglutide Demonstrates Cardiovascular Benefits Beyond Weight Loss in Meta-Analysis

A new meta-analysis reveals that semaglutide, used in diabetes and weight loss medications, significantly reduces cardiovascular risk.
The study suggests semaglutide has direct effects on heart health, including stabilizing atherosclerotic plaques and improving systemic inflammation.

Semaglutide Shows Promise in Reducing Opioid Overdose Risk in Type 2 Diabetes Patients

A recent study suggests semaglutide, used for type 2 diabetes and weight loss, may significantly reduce the risk of opioid overdose in patients with both conditions.
The study compared semaglutide to other antidiabetic medications, finding a 42% to 68% lower overdose risk in the semaglutide group over a one-year follow-up.

SGLT-2 Inhibitors Linked to Reduced Dementia and Parkinson's Risk in Type 2 Diabetes Patients

A recent study suggests that SGLT-2 inhibitors, used for type 2 diabetes, are associated with a lower risk of dementia and Parkinson's disease.
The research, involving over 220,000 type 2 diabetes patients, found a 35% reduced risk of dementia with SGLT-2 inhibitors compared to DPP-4 inhibitors.

Study Shows SGLT2 Inhibitors Improve Renal Function in Non-Diabetic CKD Patients

A recent study conducted at Maccabi Healthcare Services in Israel has demonstrated that sodium-glucose cotransporter-2 (SGLT2) inhibitors significantly improve renal function in non-diabetic individuals with chronic kidney disease (CKD). The research, which involved 354 participants, found that the administration of SGLT2 inhibitors led to a notable improvement in the estimated glomerular filtration rate (eGFR) slope over time.

SGLT2 Inhibitors Show Promising Results for Elderly with Type 2 Diabetes

A recent study utilizing the Korean National Health Insurance Service database compared the effectiveness and safety of SGLT2 inhibitors versus DPP-4 inhibitors in older adults with type 2 diabetes. Findings suggest SGLT2 inhibitors significantly reduce the risk of heart failure hospitalization, all-cause death, and stroke, despite higher risks of genital and urinary tract infections. The study highlights the need for careful consideration in prescribing SGLT2 inhibitors to very elderly patients due to diminished cardiovascular benefits.

Increased Risk of Diabetic Ketoacidosis with Sotagliflozin in Type 1 Diabetes Patients

A study evaluating the incidence and risk factors for diabetic ketoacidosis (DKA) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin found an increased incidence of DKA compared to insulin alone. The study, pooling data from two 52-week, randomized studies, observed higher DKA incidence rates with sotagliflozin, especially at higher doses. However, the implementation of a risk mitigation plan was associated with a lower incidence of DKA, suggesting that patient education and monitoring can manage this risk.

Reference News

[1]
The Efficacy and Safety of Sodium-Glucose Co-transporter ...
link.springer.com · May 21, 2024

SGLT2 inhibitors significantly improve glycemic control and reduce body weight in type 2 diabetes patients, with benefit...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy